What is the main purpose of this 8-K filing?

The primary purpose of this 8-K filing is to formally announce that the High Court of Justice in England and Wales has sanctioned the scheme of arrangement for Boston Scientific's acquisition of BTG plc. This is a critical legal milestone for the transaction.

What does the court sanctioning the scheme of arrangement mean for the BTG acquisition?

The court's sanction means that a major legal hurdle for the acquisition has been cleared. It allows the transaction to proceed towards completion, subject to any other outstanding conditions stipulated in the scheme document.

What are the next steps for the BTG acquisition after this court sanction?

While the exact next steps depend on the specific terms outlined in the scheme document, the court sanction generally clears the path for the transaction to close. This may involve final regulatory approvals or other customary closing conditions being met.

Is this filing an offer to buy or sell securities?

No, this filing explicitly states that it does not constitute an offer to sell or subscribe for, or any invitation to purchase or subscribe for, any securities. Investors should rely on the official scheme document for details regarding the acquisition.

BSX 8-K SEC Disclosure — Aug 15, 2019

Summary

Boston Scientific Corporation (BSX) filed an 8-K on August 15, 2019, to announce a significant development in its previously announced acquisition of BTG plc. The High Court of Justice in England and Wales has officially sanctioned the court-sanctioned scheme of arrangement (the "Scheme") for the acquisition. This sanction is a crucial legal step required to finalize the transaction under UK law. The successful sanctioning of the Scheme by the court paves the way for the completion of the BTG acquisition, subject to any remaining closing conditions. Investors should view this as positive news, indicating that the acquisition is progressing as planned and nearing completion. This move is strategic for Boston Scientific, aiming to expand its presence and product offerings, particularly in the interventional medicine space where BTG has a strong portfolio.

Key Highlights

1Boston Scientific's acquisition of BTG plc has received court sanction from the High Court of Justice in England and Wales.
2This sanction is a key legal requirement for the scheme of arrangement to proceed under UK law.
3The announcement was made via an RNS (Regulatory News Service) release on the London Stock Exchange.
4This filing (Item 8.01) confirms a major step towards the completion of the BTG acquisition.
5The acquisition is being implemented through Bravo Bidco Limited, an indirect wholly-owned subsidiary of Boston Scientific.
6This filing does not constitute an offer to sell or solicit an offer to buy securities.

BOSTON SCIENTIFIC CORP 8-K Report, Corporate Update (Aug 15, 2019)

Summary

Key Highlights

Frequently Asked Questions